4D Molecular Therapeutics, Inc. (FDMT)
10.80
-1.05
(-8.86%)
USD |
NASDAQ |
Oct 23, 16:00
10.78
-0.02
(-0.23%)
After-Hours: 20:00
4D Molecular Therapeutics Net Income (Quarterly) : -72.94M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -72.94M |
| March 31, 2026 | -68.76M |
| December 31, 2025 | 19.40M |
| September 30, 2025 | -56.88M |
| June 30, 2025 | -54.66M |
| March 31, 2025 | -47.97M |
| December 31, 2024 | -49.67M |
| September 30, 2024 | -43.84M |
| June 30, 2024 | -34.95M |
| March 31, 2024 | -32.40M |
| September 30, 2023 | -10.26M |
| June 30, 2023 | -29.62M |
| March 31, 2023 | -28.68M |
| Date | Value |
|---|---|
| December 31, 2022 | -27.38M |
| September 30, 2022 | -25.69M |
| June 30, 2022 | -28.09M |
| March 31, 2022 | -26.34M |
| December 31, 2021 | -25.08M |
| September 30, 2021 | -22.24M |
| June 30, 2021 | -7.589M |
| March 31, 2021 | -16.41M |
| September 30, 2020 | -7.833M |
| June 30, 2020 | -15.15M |
| March 31, 2020 | -13.16M |
| December 31, 2019 | -16.12M |
| September 30, 2019 | -16.68M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
| Imunon, Inc. | -2.814M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.781M |
| Total Expenses (Quarterly) | 76.72M |
| EPS Diluted (Quarterly) | -1.038 |
| Enterprise Value | 274.20M |
| Gross Profit Margin (Quarterly) | 44.75% |
| Profit Margin (Quarterly) | -1.93K% |
| Earnings Yield | -25.23% |
| Normalized Earnings Yield | -25.23 |